Cargando…

Cerebrospinal fluid biomarkers in Alzheimer’s disease, vascular dementia and ischemic stroke patients: a critical analysis

Vascular factors are thought to contribute to the development of disease pathology in neurodegenerative dementia such as Alzheimer’s disease (AD). Another entity, called vascular dementia (VaD), comprises a less defined group of dementia patients having various vascular diseases that especially emer...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaerst, Lisa, Kuhlmann, Andre, Wedekind, Dirk, Stoeck, Katharina, Lange, Peter, Zerr, Inga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825487/
https://www.ncbi.nlm.nih.gov/pubmed/23877436
http://dx.doi.org/10.1007/s00415-013-7047-3
_version_ 1782290798775107584
author Kaerst, Lisa
Kuhlmann, Andre
Wedekind, Dirk
Stoeck, Katharina
Lange, Peter
Zerr, Inga
author_facet Kaerst, Lisa
Kuhlmann, Andre
Wedekind, Dirk
Stoeck, Katharina
Lange, Peter
Zerr, Inga
author_sort Kaerst, Lisa
collection PubMed
description Vascular factors are thought to contribute to the development of disease pathology in neurodegenerative dementia such as Alzheimer’s disease (AD). Another entity, called vascular dementia (VaD), comprises a less defined group of dementia patients having various vascular diseases that especially emerge in the elderly population and require valid options for examination and differential diagnosis. In the context of a retrospective study, we analyzed the cerebrospinal fluid (CSF) biomarkers t-tau, p-tau and Aß42 of a total of 131 patients with AD (n = 47), mild cognitive impairment (MCI) (n = 22), VaD (n = 44) and stroke (n = 18). We found a remarkable alteration in CSF biomarker profile in AD, VaD and in acute ischemic events. CSF profile in AD patients was altered in a very similar way as in stroke patients, without statistical differences. In stroke, increase depend largely on size and duration after the initial event. Total tau levels were useful to differ between VaD and stroke. Aß42 decreased in a similar way in AD, VaD and stroke and had a trend to lower levels in MCI but not in controls.
format Online
Article
Text
id pubmed-3825487
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-38254872013-11-21 Cerebrospinal fluid biomarkers in Alzheimer’s disease, vascular dementia and ischemic stroke patients: a critical analysis Kaerst, Lisa Kuhlmann, Andre Wedekind, Dirk Stoeck, Katharina Lange, Peter Zerr, Inga J Neurol Original Communication Vascular factors are thought to contribute to the development of disease pathology in neurodegenerative dementia such as Alzheimer’s disease (AD). Another entity, called vascular dementia (VaD), comprises a less defined group of dementia patients having various vascular diseases that especially emerge in the elderly population and require valid options for examination and differential diagnosis. In the context of a retrospective study, we analyzed the cerebrospinal fluid (CSF) biomarkers t-tau, p-tau and Aß42 of a total of 131 patients with AD (n = 47), mild cognitive impairment (MCI) (n = 22), VaD (n = 44) and stroke (n = 18). We found a remarkable alteration in CSF biomarker profile in AD, VaD and in acute ischemic events. CSF profile in AD patients was altered in a very similar way as in stroke patients, without statistical differences. In stroke, increase depend largely on size and duration after the initial event. Total tau levels were useful to differ between VaD and stroke. Aß42 decreased in a similar way in AD, VaD and stroke and had a trend to lower levels in MCI but not in controls. Springer Berlin Heidelberg 2013-07-23 2013 /pmc/articles/PMC3825487/ /pubmed/23877436 http://dx.doi.org/10.1007/s00415-013-7047-3 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Communication
Kaerst, Lisa
Kuhlmann, Andre
Wedekind, Dirk
Stoeck, Katharina
Lange, Peter
Zerr, Inga
Cerebrospinal fluid biomarkers in Alzheimer’s disease, vascular dementia and ischemic stroke patients: a critical analysis
title Cerebrospinal fluid biomarkers in Alzheimer’s disease, vascular dementia and ischemic stroke patients: a critical analysis
title_full Cerebrospinal fluid biomarkers in Alzheimer’s disease, vascular dementia and ischemic stroke patients: a critical analysis
title_fullStr Cerebrospinal fluid biomarkers in Alzheimer’s disease, vascular dementia and ischemic stroke patients: a critical analysis
title_full_unstemmed Cerebrospinal fluid biomarkers in Alzheimer’s disease, vascular dementia and ischemic stroke patients: a critical analysis
title_short Cerebrospinal fluid biomarkers in Alzheimer’s disease, vascular dementia and ischemic stroke patients: a critical analysis
title_sort cerebrospinal fluid biomarkers in alzheimer’s disease, vascular dementia and ischemic stroke patients: a critical analysis
topic Original Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825487/
https://www.ncbi.nlm.nih.gov/pubmed/23877436
http://dx.doi.org/10.1007/s00415-013-7047-3
work_keys_str_mv AT kaerstlisa cerebrospinalfluidbiomarkersinalzheimersdiseasevasculardementiaandischemicstrokepatientsacriticalanalysis
AT kuhlmannandre cerebrospinalfluidbiomarkersinalzheimersdiseasevasculardementiaandischemicstrokepatientsacriticalanalysis
AT wedekinddirk cerebrospinalfluidbiomarkersinalzheimersdiseasevasculardementiaandischemicstrokepatientsacriticalanalysis
AT stoeckkatharina cerebrospinalfluidbiomarkersinalzheimersdiseasevasculardementiaandischemicstrokepatientsacriticalanalysis
AT langepeter cerebrospinalfluidbiomarkersinalzheimersdiseasevasculardementiaandischemicstrokepatientsacriticalanalysis
AT zerringa cerebrospinalfluidbiomarkersinalzheimersdiseasevasculardementiaandischemicstrokepatientsacriticalanalysis